BOTHELL, Wash.– Seagen Inc. (Nasdaq:SGEN) today announced the appointment of Lee Heeson as Executive Vice President, Commercial International. Heeson has nearly 30 years of industry experience, and will have responsibility for the continued expansion of Seagen’s Commercial operations in Europe, Canada and the rest of the world outside the United States. He will be a member of Seagen’s Executive Committee and report to Clay Siegall, Ph.D., President and Chief Executive Officer of Seagen. Heeson succeeds Tuomo Pätsi, who will retire effective February 4, 2022.
“Lee is an accomplished industry executive, and we are pleased to welcome him as the new leader of our Commercial International organization,” said Dr. Siegall. “We have strong momentum in bringing TUKYSA to patients outside the United States. Lee’s considerable experience will serve us well as we continue to prepare for TUKYSA launches in a number of European countries this year, as well as deliver on the recent launch of PADCEV in Canada and grow our ex-U.S. operations. We thank Tuomo for his excellent leadership and wish him well in retirement.”
Most recently, Heeson was President of International at Vifor Pharma in Switzerland. Previously, he was President of Worldwide Markets at Celgene following other executive positions at the company. Earlier in his career he held leadership positions at Galderma and Schering-Plough.
Heeson will be based at Seagen’s International Headquarters in Zug, Switzerland.
